Your browser doesn't support javascript.
Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19.
Kumbhakar, Raaka; Neradilek, Moni; Barnabas, Ruanne V; Stewart, Jenell; Stankiewicz Karita, Helen C; Landovitz, Raphael J; Kissinger, Patricia J; Jerome, Keith R; Paasche-Orlow, Michael K; Bershteyn, Anna; Chu, Helen Y; Neuzil, Kathleen M; Greninger, Alexander L; Luk, Alfred; Wald, Anna; Brown, Elizabeth R; Johnston, Christine.
  • Kumbhakar R; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Neradilek M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Barnabas RV; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Stewart J; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Stankiewicz Karita HC; Department of Epidemiology, University of Washington, Seattle, Washington, USA.
  • Landovitz RJ; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Kissinger PJ; Department of Global Health, University of Washington, Seattle, Washington, USA.
  • Jerome KR; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Paasche-Orlow MK; Department of Medicine, Division of Infectious Diseases, UCLA Center for Clinical AIDS Research & Education (CARE), University of California, Los Angeles, California, USA.
  • Bershteyn A; School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.
  • Chu HY; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Neuzil KM; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Greninger AL; General Internal Medicine, Boston University School of Medicine, Boston, Massachusettes, USA.
  • Luk A; Boston Medical Center, Boston, Massachusettes, USA.
  • Wald A; Department of Population Health, New York University Grossman School of Medicine, New York, New York, USA.
  • Brown ER; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Johnston C; Department of Epidemiology, University of Washington, Seattle, Washington, USA.
J Med Virol ; 94(12): 6091-6096, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-2059508
ABSTRACT
Two randomized controlled trials demonstrated no clinical benefit of hydroxychloroquine (HCQ) for either postexposure prophylaxis or early treatment of SARS-CoV-2 infection. Using data from these studies, we calculated the time-weighted average change from baseline SARS-CoV-2 viral load and demonstrated that HCQ did not affect viral clearance.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.28054

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.28054